Assertio Therapeutics Inc

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Assertio Therapeutics Inc reports stellar Q4 performance and growth outlook

Assertio Therapeutics Inc (ASRT) delivered a robust Q4 performance with significant revenue and profit growth, despite facing challenges like supply issues.
The company's strategic focus on marketing, product development, and business expansion highlights a commitment to long-term success and shareholder value.
With a positive outlook for 2023 and a strong foundation in place, ASRT is poised for continued growth and value creation in the pharmaceutical market.

Assertio Therapeutics Inc (ASRT) reports robust Q1 results and raises 2023 guidance

Assertio Therapeutics Inc (ASRT) demonstrated solid financial performance in Q1 2023, with strong sales growth and improved profitability.
The company's strategic execution and upcoming acquisitions signal a positive outlook for future growth and expansion.
While facing integration challenges and market competition, Assertio's focus on product sales and operational efficiency bodes well for sustained success.

Assertio Therapeutics reports strong Q2 growth amidst generic competition

Assertio's Q2 performance showcased growth driven by key products and the acquisition of Spectrum Pharmaceuticals, positioning the company for future success.
While facing challenges from generic competition and operational expenses, Assertio remains focused on defending market share and creating shareholder value.
Management's confidence in overcoming short-term obstacles underscores a proactive approach to navigating market dynamics and driving growth.

Assertio Therapeutics Inc reports resilient Q3 performance amidst challenges

Assertio Therapeutics Inc navigated challenges in Q3 2023 with resilience, reporting positive financial metrics and improved liquidity.
New management changes and a focus on market access signal the company's commitment to driving growth and optimizing operations.
Despite lower sales for certain products, Assertio's strategic initiatives and financial performance position it well for future opportunities.
Analyst inquiries during the call highlighted areas for improvement and growth, indicating a proactive approach to addressing market dynamics.

Assertio Therapeutics reports robust Q4 results and outlines growth plans

Assertio Therapeutics Inc (ASRT) demonstrated strong financial performance in Q4 2023, driven by robust sales and positive EBITDA.
The company's strategic focus on Rolvedon's growth, profitability optimization, and future acquisitions positions it well for continued success.
While facing challenges from generic competition and operational issues, Assertio is poised to capitalize on growth opportunities and drive value creation.

Assertio Therapeutics Inc meets Q1 targets, eyes growth opportunities

Assertio Therapeutics Inc's Q1 2024 showcased strong sales performance, cost management, and cash generation. Despite challenges in generic competition and CEO transition, the company remains focused on growth opportunities.

Assertio Therapeutics reports solid Q2 results and projects growth

Assertio Therapeutics Inc (ASRT) demonstrated financial stability, growth potential, and resilience in the face of market challenges during Q2 2024.
The company's strategic focus on key products like Rolvedon and effective cost management strategies position it well for future success and profitability.
Maintaining guidance for 2024 and leveraging opportunities for growth underscore Assertio's commitment to delivering value to shareholders and stakeholders.

Assertio Therapeutics reports stable Q3 performance amid ROLVEDON transition

Assertio Therapeutics demonstrated stable financial performance and operational efficiency in Q3 2024, positioning the company for growth amidst challenges.
The company's focus on ROLVEDON and governance enhancements signal a strategic shift towards innovation and stakeholder value creation.
While facing challenges such as declining product sales and financial constraints, Assertio remains resilient and poised to capitalize on opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc. (NASDAQ:ASRT ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, IR Dan Peisert - President and CEO Ajay Patel - SVP & Chief Accounting Officer Paul Schwichtenberg - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Jim Sidoti - Sidoti Scott Henry - ROTH MKM Partners Operator Good morning and welcome to the Assertio Holdings Inc. Third Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

Assertio Holdings Inc. (ASRT) Q3 2023 Earnings Call Transcript

Closed Spectrum Acquisition on July 31, 2023, which diversifies and extends portfolio duration  Cash balance at September 30, 2023 of $76.9 million  Announces Management Updates

Assertio Reports Third Quarter 2023 Financial Results

LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 2023

Assertio Holdings has undergone a significant transformation in its business model, reducing debt and exiting the opioid business. The company's recent performance has shown strong growth, with increased net product sales and improved gross margin. Assertio's stock is currently undervalued, trading at a significant discount, and has the potential for future growth and a turnaround.

Assertio Holdings: Uncovering A Tapestry Of Trading Opportunities From This Oversold Ticker

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?

Assertio Holdings has experienced extreme price volatility, but the current price presents a buying opportunity. The company has diversified its pharmaceutical portfolio and improved its financial position, positioning it for future growth. Risks include generic competition, market and regulatory uncertainties, legal liabilities, and product discontinuation.

Growth And Pain Make Assertio A Deep Value Buy

Assertio (NASDAQ: ASRT ) stock is falling hard on Friday after the pharmaceutical company released its Q2 earnings report. Assertio disappointed investors with its adjusted earnings per share of 19 cents.

Why Is Assertio (ASRT) Stock Down 46% Today?

Assertio (ASRT) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.16 per share a year ago.

Assertio (ASRT) Q2 Earnings Miss Estimates

Second Quarter Net Product Sales Increase 13% Year-Over-Year, Generates $18.6 Million in Cash Flow from Operations

Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition

Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products

Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and contingent value rights (CVR) transaction.

Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals

The stock is down 33% from its 52-week high. Q2 revenue estimates are low. Lead product's use may be expanding.

Assertio Holdings Is Back As A High-Value Play

LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release second quarter 2023 financial results on Thursday, August 3, 2023, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

Kinross Gold

Rocket Lab USA

The Supreme Court recently nullified the Biden administration's proposed student loan forgiveness program in a 6-3 ruling. Seen as overreaching the authority of the executive branch, this program intended to forgive nearly $430 billion in loans.

3 Cheap Penny Stocks to Buy Before They Bounce Back

Spectrum Pharma

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) to Assertio Holdings, Inc. (NasdaqCM: ASRT). Under the terms of the proposed transaction, shareholders of Spectrum will receive, for each share of Spectrum that they own, 0.1783 shares of Assertio and one contingent value right for the right to receive $0.10 paya.

SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI

LAKE FOREST, Ill., June 26, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company, today announced that it has joined the broad-market Russell 3000 Index as part of the 2023 reconstitution, completed at the close of market on June 23.

Assertio Holdings Joins Russell 3000® Index

Assertio is a late-stage pharmaceutical company that has shown significant growth and cost savings under new leadership, focusing on a low-cost, data-driven marketing model. The company's leading product, Indocin, has seen increased sales and a recent 5x market expansion not yet included in company guidance. Assertio ranks in the top 1% of stocks in both value and high-quality momentum.

Assertio: Cheap And Growing Disruptor Of Pharma's Antiquated Sales Model

Share portion of takeover by Assertio Holdings covers the value of the shares plus a merger spread. Contingent value rights on their drug are also included, adding up to $0.20 per share. CVR payout will require aggressive sales growth, but they're effectively free.

Assertio Holdings: Spectrum Pharmaceuticals Has A Merger Spread Plus A Free CVR

Assertio Holdings, a pharmaceutical company, has demonstrated solid financials and growth potential, with a focus on reducing debt levels and increasing cash generation through strategic acquisitions. The company's liquidity position has improved over the past few years, with increasing current and cash ratios indicating a well-managed leverage condition. Despite potential risks such as increasing competition from generics and supply chain vulnerabilities, Assertio's strong financial structures and progress make it a suitable buy-rated stock.

Assertio Holdings: Promising Small Cap With Strong Financials And Strategic Plans

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Assertio Holdings, Inc. (NASDAQ: ASRT) and Spectrum Pharmaceuticals, Inc. is fair to Assertio shareholders. Halper Sadeh encourages Assertio shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Assertio and its bo.

ASRT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Assertio Holdings, Inc. Is Fair to Shareholders

In Q1 FY2023, Assertio achieved significant progress in executing the new strategy brought on board by CEO Dan Peisert. The market expects ASRT's EPS to decline nearly 82% YoY in FY2023, but then rebound strongly, with a compound annual growth rate [CAGR] of 23.7% over the next 3 years. I reiterate my previous "Buy" rating and set a 12-month price target of $10.16 per share, implying an upside potential of 60% over the medium term.

Assertio Holdings Stock Is Setting Up Again

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2023 Results Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President and Chief Executive Officer Paul Schwichtenberg - Senior Vice President and Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - ROTH Capital William Wood - B. Riley Securities Hamed Khorsand - BWS Financial Mitra Ramgopal - Sidoti & Company Operator Good afternoon and welcome to the Assertio Holdings, Inc. First Quarter 2023 Financial Results Conference Call.

Assertio Holdings, Inc. (ASRT) Q1 2023 Earnings Call Transcript

Assertio (ASRT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.13. This compares to earnings of $0.20 per share a year ago.

Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates

Net Product Sales Increase 18% Year-Over -Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum Pharmaceuticals in All Stock and CVR Transaction, Expected to be Significantly Accretive to Adjusted EPS and Operating Cash Flow in 2024 LAKE FOREST, Ill., May 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the first quarter ended March 31, 2023.

Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook

LAKE FOREST, Ill., May 05, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, before the market open. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 11:30 a.m. Eastern Time. The schedule change is in order to ensure compliance with SEC disclosure requirements in light of the pending transaction with Spectrum Pharmaceuticals, Inc.

News for Assertio Therapeutics Inc Stock (ASRT)